Cytox & Affymetrix Form Strategic Partnership to Develop & Commercialize Blood-Based Genetic Assay for Alzheimer’s Disease ...
20 July 2015 - 8:30PM
Business Wire
Cytox Ltd, an innovative developer of assays for risk assessment
and prediction of dementia, and Affymetrix (Nasdaq:AFFX), a leading
provider of translational research and diagnostic solutions,
announce a strategic partnership where the two companies are to
collaborate on developing and commercializing a blood-based genetic
assay for research in diagnosis and prognosis of Alzheimer’s
disease (AD) and Mild Cognitive Impairment (MCI).
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150720005017/en/
Dr. Richard Pither, CEO of Cytox commented, “Our early research
studies developed with our partners at University College London
and University of Birmingham suggest that by using a customised
genetic variation (SNP) panel, it may be possible to better assess
the risk of an individual developing AD or MCI. The Axiom®
genotyping platform from Affymetrix, a highly robust,
cost-effective, and fast turn-around time genotyping platform, is
ideally suited for use in a blood-based test for researchers
interested in AD and MCI risk stratification and longer term
diagnostic and prognostic use. Affymetrix is a leading supplier of
translational research and diagnostic solutions partnering
worldwide with customers in pharma, diagnostic and biotech
companies. Cytox will provide new genetic content using our
comprehensive AD and dementia expertise which, when combined with
Affymetrix’s technology, know-how and marketing support makes an
ideal partnership.”
“Our Axiom genotyping platform has already proved very
successful in pharma R&D,” added Michael Nemzek, VP of
Strategic Marketing, Genotyping, at Affymetrix. “The partnership
with Cytox will allow us to extend our offering into the important
AD and dementia research market with a significant new
application.”
-ends-
Cytox Limited
Cytox Limited is a UK-based company with a unique scientific and
proprietary technology platform. Through the application of this
fundamental science and our specific know-how, we are elucidating
the biology and genetics behind dementia, as well as developing
prognostic tests for cognitive decline and individual risk of
developing Alzheimer’s disease or other dementias.
For more about the mTOR pathway and its potential role in early
identification of risk of dementia and Alzheimer’s disease, follow
this link: www.cytoxgroup.com/information-for-editors
Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness.
Affymetrix provides leadership and support, partnering with
customers in pharmaceutical, diagnostic, and biotechnology
companies, as well as leading academic, government, and non-profit
research institutes in their quest to use biology for a better
world. More than 2,300 microarray systems have been shipped around
the world and more than 94,000 peer-reviewed papers have been
published citing Affymetrix technologies. Affymetrix is
headquartered in Santa Clara, California, and has manufacturing
facilities in Cleveland, San Diego, Vienna, and Singapore.
Affymetrix has about 1,100 employees and maintains sales and
distribution operations worldwide.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, and
Axiom trademarks are the property of Affymetrix, Inc. All
other trademarks are the property of their respective owners.
For more information about Affymetrix, please visit
www.affymetrix.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150720005017/en/
Cytox LimitedRichard Pither, CEO,+44 (0)1865
338018Richard.pither@cytoxgroup.comwww.cytoxgroup.comAffymetrixMedia
ContactMindy Lee-OlsenVP, Marketing Services+1 408 731
5523Mindy_lee-olsen@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024